REMARKS

In the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office mailed April 13, 2006, the Patent Office found that this application failed to comply with the requirements of 37 C.F.R. 1.821-1.825. In particular, the Office states:

> This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825.

No further explanation is provided, but the paper further goes on to require a copy of "the 'Sequence Listing" in computer readable form."

Applicant respectfully disagrees that 37 C.F.R. 1.821-1.825 applies to the present application.

The Manual of Patent Examining Procedure §2422.03 states,

> In those instances in which prior art sequences are only referred to in a given application by name and a publication or accession reference, they need not be included as part of the "Sequence Listing," unless an examiner considers the referred-to sequence to be "essential material," per MPEP §608.01(p).

The proteins referred to in this application fall squarely within this exempt category of prior art sequence information described above. The proteins referred to within the application (which the Examiner did NOT describe as "essential material" in the Notification of Missing Requirements) *consist only of prior art proteins referred to by name and a publication or accession reference expressly as provided in the MPEP section above.* Specifically, the sequence information found within the application is described below for the GLUT family of transporter proteins referred to in the application (and including publications for each protein from GLUT-1 through GLUT-13:

> Details for the various GLUT proteins can be found for example for GLUT-1 in Mueckler et al (1985) Science 229, 941-985; and Fukumoto, et al (1989) Diabetes 37, 657-661. GLUT-2: Fukumoto et al (1989) J. Biol. Chem 264, 7776-7779; GLUT-3: Kayano et al (1988) J. Biol. Chem 263, 15245-15248; GLUT-4: Fukumoto et al (1989) J. Biol. Chem

2